 
 
 
 
 
Protocol: I5T -MC -AACP(a)  
 
 
A Phase 1, Open -Label Study to Characterize the 
Pharmacokinetics of Donanemab Following Intravenous Doses in Healthy Participants  
 
 
[STUDY_ID_REMOVED] 
 
 
Approval Date: 12 Dec 2022  
CONFIDENTIAL  I5T-MC-AACP (a) 
1 Title Page   
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of donanemab  (LY3002813 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commerciall y confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 a nd may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:   
A Phase 1 , Open-Label Study to Characterize  the Pharmacokinetics  of Donanemab  Following 
Intravenous Doses in Healthy Participants  
Protocol Number:  I5T-MC-AACP  
Amendment Number: a  
Compound : LY300 2813  
Brief  Title:  
A Study to Characterize  the Pharmacokinetics of  Donanemab  Following Intravenous Dose s in 
Healthy Participants  
Study Phase:  Phase 1  
Acronym : AACP  
Sponsor Name:  Eli Lilly and Company  
Legal Registered Address:  Eli Lilly and Company, Indianapolis, Indiana USA 46285  
Regulatory Agency Identifier Number : IND: 109157  
Approval Date:  Protocol Electronically  Signed and  Approved  by Lilly  on date provided below .  
Document ID:  VV-CLIN -076261  
 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
2 Medical Monitor Name and Contact Information will be provided separately . 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
3 Protocol Amendment Summary of Changes Table   
 
DOCUMENT HISTORY  
Document  Date  
Original Protocol  31-Aug-2022  
Amendment (a)  
This amendment is considered to be  nonsubstantial.  
Overall Rationale for the Amendment:  
The protocol was amended to increase the number of participants who may enroll in the study  to 
ensure the required number of subjects complete the study  and to make minor procedural 
updates.   
Minor changes were needed for consistency with in the protocol an d between the protocol and 
informed consent form ( ICF). 
 
Section # and 
Name  Description of Change  Brief Rationale  
Section 1.1 Synopsis  Updated number of participants who may 
be enrolled . 
 
 
Added “IV” when discussing study design 
and summary . Approximately  40 participants may be 
enrolled  to ensure the required number of 
subjects complete the study . 
 
To be more specific regarding type of 
administration . 
Section 1.3 Schedule 
of Activities  Added a note that height is measured  at 
screening  only. There is no ne ed for height  to be 
measured at other timepoints.  
Section 4.1 Overall 
Design  Updated number of participants who may 
be enrolled . 
 
Added “IV” when discussing study design 
and summary . Approximately 40 participants may be 
enrolled.  
 
To be more specific regarding type of 
administration . 
Section 4.3 
Justification for Dose  Added “IV” for the dose selected for this 
study . To be more specific regarding type of 
administration . 
Section 5.3 Lifestyle 
Considerations  Changed when participants should abstain 
from  alcohol from “until after collection of 
the final PK sample” to “until lea ving the 
CRU ”. To align with alcohol restrictions set out 
in Exclusion Criteria 30  and in the ICF . 
Section 8 Study 
Assessments and 
Procedures  Removed “in the CRF”  from the line 
regarding recording of actual time . Actual time s need to be recorded , but not  
in the CRF . 
Section 9.5 Sample 
Size Determination  Updated number of participants who may 
be enrolled . Approximately 40 participants may be 
enrolled.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
4 Section # and 
Name  Description of Change  Brief Rationale  
Section 10.7 
Appendix  7 Removed sentence stating that “This is 
documented as a screen failure in the 
CRF” . EMP does not capture screen failures in 
the CRF . 
Abbreviations: CRF  = case report form; CRU  = clinical research unit; EMP  = Exploratory Medicine and 
Pharmacology ; ICF = informed consent form; IV = intravenous ; PK = pharmacokinetics .  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
5 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ ............................ 11 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 12 
2. Introduction  ................................ ................................ ................................ ................... 15 
2.1. Study Rationale  ................................ ................................ ................................ ............... 15 
2.2. Background  ................................ ................................ ................................ ..................... 15 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 16 
3. Objectives and Endpoints  ................................ ................................ ............................ 19 
4. Study Design  ................................ ................................ ................................ .................. 20 
4.1. Overall  Design  ................................ ................................ ................................ ................ 20 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 20 
4.3. Justification for Dose  ................................ ................................ ................................ ......21 
4.4. End of Study Definition  ................................ ................................ ................................ ..21 
5. Study Population  ................................ ................................ ................................ ........... 22 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 22 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 23 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .25 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 25 
5.3.2.  Substance Use: Caffeine, Alcohol, and Tobacco  ................................ ............................ 25 
5.3.3.  Activity  ................................ ................................ ................................ ........................... 25 
5.4. Screen Failures  ................................ ................................ ................................ ................ 25 
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Participant  ................................ ................................ ................................ ................ 25 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 26 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 26 
6.1.1.  Administration Details  ................................ ................................ ................................ ....26 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 27 
6.3. Assignment to Study Intervention  ................................ ................................ .................. 27 
6.4. Blinding  ................................ ................................ ................................ .......................... 27 
6.5. Study Intervention Compliance  ................................ ................................ ...................... 28 
6.6. Dose Modification  ................................ ................................ ................................ .......... 28 
6.7. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 28 
6.8. Treatment of Overdose  ................................ ................................ ................................ ...28 
6.9. Prior and Concomitant Therapy  ................................ ................................ ...................... 28 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 30 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 30 
7.1.1.  Liver Chemistry Stopping Criteria  ................................ ................................ .................. 30 
7.2. Participa nt Discontinuation/Withdrawal from the Study  ................................ ................ 32 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
6 7.3. Lost to Follow up  ................................ ................................ ................................ ............ 33 
8. Study Assessments and Procedures ................................ ................................ ............. 34 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....34 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 34 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....34 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 35 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ ......... 35 
8.2.4. Clinical Safety Laboratory Tests  ................................ ................................ .................... 35 
8.2.5.  Pregnancy Testing  ................................ ................................ ................................ ........... 36 
8.2.6.  Neurological Examination  ................................ ................................ .............................. 36 
8.2.7.  Suicidal Ideation and  Behavior Risk Monitoring  ................................ ........................... 37 
8.2.8.  Safety Monitoring  ................................ ................................ ................................ ........... 37 
8.3. Adverse Events, Serious Adverse Events, and Product 
Complaints  ................................ ................................ ................................ ...................... 41 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 42 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 44 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 45 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 45 
8.6. Genetics  ................................ ................................ ................................ .......................... 45 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 45 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 45 
8.9. Health Economics  ................................ ................................ ................................ ........... 46 
9. Statistical Considerations  ................................ ................................ ............................. 47 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....47 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..47 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 47 
9.2.1.  Study Participant Disposition  ................................ ................................ ......................... 47 
9.2.2.  Study Participant Characteristics  ................................ ................................ .................... 47 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 47 
9.3.1.  General Considerations  ................................ ................................ ................................ ...47 
9.3.2.  Primary Endpoint Analyses: Pharmacokinetic Analyses  ................................ ................ 48 
9.3.3.  Secondary Endpoint(s) Analyses  ................................ ................................ .................... 48 
9.3.4.  Exploratory Analyses  ................................ ................................ ................................ ......48 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 49 
9.3.6. Immunogenicity Assessments  ................................ ................................ ......................... 49 
9.3.7.  Other Analyses  ................................ ................................ ................................ ................ 49 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 49 
9.5. Sample Size Determination  ................................ ................................ ............................ 50 
10. Supporting Documentation and Operational Considerations  ................................ ..51 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Consi derations  ................................ ................................ ................................ ................ 51 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 51 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 52 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 52 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 52 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
7 10.1.5.  Committees Structure ................................ ................................ ................................ ......52 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 53 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..53 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 54 
10.1.9.  Study and Site Start and Closure  ................................ ................................ .................... 55 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 55 
10.1.11.  Investigator Information  ................................ ................................ ................................ .56 
10.1.12.  Long -Term Sample Retention ................................ ................................ ......................... 56 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 57 
10.2.1.  Blood Sampling Summary  ................................ ................................ .............................. 59 
10.2.2.  Laboratory Samples to be Obtained at the Time of a Systemic 
Hypers ensitivity Event  ................................ ................................ ................................ ....59 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ 61 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 61 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ........... 62 
10.3.3.  Definition of Product Compla ints ................................ ................................ ................... 63 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 63 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 66 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 66 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 67 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 67 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..67 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......69 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 70 
10.7.  Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 72 
10.8.  Appendix 8:  Abbreviations and Definitions  ................................ ................................ ...75 
11. References  ................................ ................................ ................................ ...................... 78 
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
8 1. Protocol Summary   
1.1. Synopsis   
Proto col Title:   
A Phase 1 , Open -Label S tudy to Characterize the Pharmacokinetics of  Donanemab  Following 
Intravenous Doses  in Healthy P articipants  
Brief  Title:   
A Study to Characterize the Pharmacokinetics of Donanemab Following Intravenous Doses in 
Healthy Participants  
Regulatory Agency Identifier Number : 
IND: 109157  
Rationale :   
Study I5T -MC-AACP (AACP) will investigate the pharmacokinetics (PK) and safety of 
intravenous (IV) administration of donanemab in healthy participants every 2 weeks (Q2W) for 
10 weeks at a 350  mg dose to support dosing regimens in future studies . 
Objectives  and Endpoint s: 
Objectives  Endpoints  
Primary   
 To characterize the PK profile of 
donanemab following administration 
of 350  mg IV doses in healthy 
participants   AUC  0-4Weeks 
 Cmax,ss , and  
 AUC t,ss  
Secondary   
 To investigate the safety and 
tolerability of donanemab following 
administration of 350  mg IV doses in 
healthy participants   Incidence of treatment -emergent 
adverse events and serious adverse 
events  
Abbreviations: AUC ,ss = area under the concentration versus time curve during a dosing interval at steady state; 
AUC 0-4Weeks = area under the concentration versus time curve 0 to 4 weeks ; Cmax,ss  = maximum observed drug 
concentration during a dosing interval at steady state; I V = intravenous; PK  = pharmacokinetic.  
Overall Design :  
This is a Phase 1, open -label study to evaluate the PK, safety, and tolerability of 350 mg 
donanemab administered as a single IV dose Q2W for 1 0 weeks  in healthy participants . 
Approximately  40 participants may be enrolled so that approximately 25 participants complete 
the study. Participants will receive a single 350  mg dose of donanemab  IV Q2W  for 1 0 weeks. 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
9 After each dose administration , participants will remain in the  clinical research unit  (CRU) for 
up to 5  days. Participants will return to the CRU for regular outpatient visits until the next dose 
of donanemab. After the last dose of donanemab, participants will return for outpatient visits up 
to 12  weeks after the last dose.  
Brief Summary : 
The purpose of this study is to measure the PK of 350 mg donanemab IV adminis tered Q2W for 
10 weeks  in healthy participants .   
Study details include:  
 The study duration will be up to 22 weeks . 
 The treatment duration will be up to  10 weeks . 
 The visit frequency will be  Q2W . 
Study Population : 
Healthy participants will be enrolled in this study.  
Number of Participant s: 
Approximately  40 participants will be enrolled  to donanemab  so that approximately 
25 participants complete the study .  
Intervention Groups  and Duration : 
Screening period:  28 days prior to enrollment into the study.  
Treatment period s: On Day -1 prior to dosing of each of the 6 treatment periods , parti cipants will 
be admitted to the CRU . On Day 1 of each treatment period , participants will be dosed with  a 
single IV dose (350 mg) of donanemab  Q2W  for 1 0 weeks. After each dose administration , 
participants will remain in the  CRU for up to 5  days.  
Follow -up period: Up to 12  weeks after the last dose  of donanemab . 
Ethical Considerations of Benefit/ Risk:  
The following are the risks and discomforts associated with donanemab:  
 amyloid -related imaging abnormalities (ARIA)  
 treatment -emergent anti -drug antibodies (TE -ADAs), and  
 infusion -related reactions (IRRs) and hypersensitivity.  
In this study  (Study AACP) , amyloid -related imaging abnormality –edema/effusions (ARIA -E) 
and amyloid -related imaging abnormality –hemorrhage/hemosiderin deposition (ARIA -H) events 
are not expected given the young healthy population being enrolled. These participants are 
expecte d to not have amyloid deposits in their brain and thus the risk of ARIA -E and ARIA -H is 
considered low.  
TE-ADAs have been observed after a single dose of donanemab across all dose levels assessed, 
including the single cohort of healthy participants in Stud y I5T -MC-AACC (AACC). Therefore, 
TE-ADAs will be carefully monitored in this study.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
10 IRRs have been observed in Studies AACC, I5T -MC-AACD, and I5T -MC-AACG. All 
biological agents carry the risk of systemic allergic and hypersensitivity reactions and patients  
should be monitored for the occurrence of these reactions.  
Data Monitoring Committee: No 
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
11 1.2. Schema   
 
Abbreviation: CRU = clinical  research unit . 
 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
12 1.3. Schedule of Activities  (SoA)   
Assessment Period  Screen ing Treatment Periods 1 -6 Follow -up 
(Treatment Period 6)  ED Notes  
Study Day   -28 to -2 -1 1 2 3 4 5 8 37 96   
Informed consent  X            
Inclusion/exclusion criteria  X X X          
Admi ssion  to CRU   X           
Discharge from CRU     X X X X    
 Discharge from CRU 
can be at a minimum of 
2 days postdose  and up 
to 5 days postdose  at 
the discretion  of the 
investigator . 
Outpatient visit         X X X X  
Donanemab administration    X          
Medical history, 
demographics  X            
Weight, height, BMI  X         X X Height measured  at 
screening only.  
Physical examination , medical 
assessment X X X X   Xa  
 X X a If discharge from 
CRU is on Days 2, 3 , or 
4, physical examination 
will be taken at the 
earlier CRU discharge 
visit.  
Full physical exam at 
screening and Day -1 
and symptom -directed  
medical assessment at 
other time  points and as 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
13 Assessment Period  Screen ing Treatment Periods 1 -6 Follow -up 
(Treatment Period 6)  ED Notes  
Study Day   -28 to -2 -1 1 2 3 4 5 8 37 96   
deemed necessary by 
investigator . 
Neurological examination  X X  24 hr   Xb  X X X b If discharge from 
CRU is on D ays 2, 3 , or 
4, neurological 
examination will be 
taken at the earlier CRU 
discharge visit . 
C-SSRS  X X        X X  
Vital signs (supine): blood 
pressure, pulse rate, 
temperature  X X Predose , 
6 hr 24 hr X X X  X X X Temperature should 
only be measured at 
screening and predose 
on Day 1 . 
12-lead ECG  X  Predose        X X Single 12 -lead ECG . 
Time points may be 
added, if clinically 
indicated.  
AE and concomitant 
medications  X X X X X X X X X X X  
Clinical lab oratory  tests  X X  24 hr      X X  
Serology  X           HBV, HCV, and HIV  
Ethanol and urine drug screen  X X         
 Ethanol test (urine o r 
breath)  may be repeated 
at other time points at 
the discretion of the 
investigator.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
14 Assessment Period  Screen ing Treatment Periods 1 -6 Follow -up 
(Treatment Period 6)  ED Notes  
Study Day   -28 to -2 -1 1 2 3 4 5 8 37 96   
Pregnancy test  X         X X Females only. Serum 
pregnancy test at 
screening. Urine 
pregnancy test at all 
other  time points.  
Serum FSH X           For postmenopausal 
females only . 
PK sample   X Predose, 
End of 
infusion  24 hr 48 hr 72 hr 96 hr X X X X PK sample and 
immunogenicity sample 
should be taken at the 
same time on Day -1. 
Immunogenicity   Xc       X X X c Immunogenicity 
sample taken on Day -1 
of Treatment Periods 1, 
2, 3 and 6 . 
Pharmacogenetic s – 
apolipoprotein E genotype ε4  X          Day -1 of Treatment 
Period 1 only . 
Abbreviations: ADA = anti -drug antibody; AE = adverse event; BMI = body mass index; CRU = clinical research unit; C-SSRS = Columbia -Suicide Severity 
Rating Scale ; ECG  = electrocardiogram; ED = early discontinuation; FSH = follicle stimulating hormone ; HBV = hepatitis B virus; HCV = hepatitis C virus; 
HIV = human immunodeficiency virus; hr = hour ; PK = p harmacokinetics . 
Note: S ite should schedule activities as appropriate. In cases where several study procedures are scheduled at the same time, follow  this order of priority for 
procedures: ECG, vital signs, PK samples, ADA . 
 
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
15 2. Introduction   
LY3002813 (donanemab) is a humanized immunoglobulin (Ig) G1 antibody directed at the 
pyroglutamate formation of the third amino acid (N3pG) of amyloid beta (Aβ) epitope that is 
present only in brain amyloid plaques. It is being developed as a treatment to slow the 
progression of Alzheimer’s disease (AD).  
2.1. Study Rationale   
Study I5T -MC-AACP (AACP) will investigate the pharmacokinetics (PK) and safety of 
intravenous (IV) administration of donanemab in healthy participants every 2 weeks (Q2W) for 
10 weeks at a 350 -mg dose to support dosing regimens in future studies.  
2.2. Backgroun d  
Alzheimer’s disease is an age -related neurodegenerative disorder characterized by a  progressive 
decline in cognitive function  and a decline in ability to perform activities of daily living . It can 
ultimately lead to death due to complications of the disease. Strong genetic and biochemical  
evidence highlights a central role of the amyloid pathway in the pathogenesis of AD (Hardy and  
Selkoe , 2002).  
Pathologic hallmarks of AD iden tified at autopsy include the presence of neuritic  Aβ plaques, 
neurofibrillary tangles (Hyman et al. 2012), and neuronal loss in  brain regions important for 
cognition, such as the hippocampus and temporal cortex (Selkoe  1991). Pathological data 
obtained fr om patients with AD demonstrate that extensive plaque  deposition exists in the patient 
population well before the first memory complaint (Morris and  Price 2001; Jack et al. 2010).  
Immunotherapy is an increasingly promising therapeutic approach that is focused on using 
antibodies to facilitate clearance of pathogenetic peptides, such as the Aβ peptide 
(Avgerinos  et al. 2021). The mechanism of action of donanemab  is considered to be targeting 
and removal of existing amyloid plaque s. The clinical strategy for donanemab  is based on the 
amyloid hypothesis of AD, which states that the production and deposition of A  plaques is an 
early and necessary event in the pathogenesis of AD.  Clinica l support for this hypothesis comes 
from the demonstration that parenchymal Aβ levels are elevated before the diagnosis of AD. 
Furthermore, early in the disease, the presence of brain amyloid appears to increase the risk of 
conversion from mild cognitive i mpairment ( MCI ) to AD. It is implicit in this hypothesis that 
enhanced clearance of Aβ plaques will lead to amelioration of AD symptoms and slow 
progression of AD.  
As of 05 January 2021,  donanemab has been administered in  3 completed clinical studies  (see 
below) . A total of 243 participants have received at least 1 dose of dona nemab . Of those 
243 participants, d onanemab has been administered to 6 healthy participants and in 237 study 
participants  with MCI due to AD ; mild to moderate AD or with early symptomatic A D and 
intermediate cerebral tau burden . 
Two Phase 1 studies (Study I5T -MC-AACC [AACC] and Study I5T -MC-AACD [AACD]) have 
been conducted in participants with MCI due to AD and mild to moderate AD. In Study AACC, 
single IV dose of donanemab from  0.1 mg/kg to 10  mg/kg was administered in single -ascending 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
16 dose phase, and IV doses from 0.3 mg/kg to 10  mg/kg once per month for a total of 4 doses were 
administered in multiple -ascending dose phase. In addition, a single IV dose of 1  mg/kg 
donanemab was  administered to a single cohort of healthy participants. In Study  AACD, single 
and multiple doses from 10 mg/kg to 40  mg/kg were administered. In both studies, rapid and 
sustained reduction in cerebral amyloid plaques were observed with donanemab doses 
10 mg/kg.  
One Phase 2 study (Study I5T -MC-AACG [AACG]) has been conducted in participants with 
early symptomatic AD and intermediate (low  to medium) cerebral tau burden. In Study  AACG, 
700 mg of donanemab IV once every 4  weeks (Q4W) for first 3 doses followed by 1400  mg 
Q4W for up to 72 weeks was administered. Treatment with donanemab  compared with placebo 
resulted in a significant slowing (32% ; p = 0.04 ) of disease progression, as measured by the 
integrated Alzheimer’s Disease Rating Scale (iADRS; Wes sels et al. 2015) , as well as deep and 
rapid reduction in amyloid plaque level.  
Key safety findings  from these completed studies  include d amyloid -related imaging 
abnormalities (ARIA ), infusion -related reactions (IRR), and the presence of treatment -emergent  
anti-drug antibodies (TE-ADAs ). The most common treatment -emergent adverse events 
(TEAEs) observed were:  
 ARIA –edema/effusions (ARIA -E) 
 ARIA –hemorrhage/hemosiderin deposition (ARIA -H)  
 superficial siderosis of central nervous system  
 IRRs  
 fall 
 headache  
 dizziness  
 upper respiratory tract infections, and  
 urinary tract infection.  
A high proportion of patients receiving donanemab have TE-ADA (92.2%; additional detail 
available in the IB). While patients experiencing hypersensitivity events were more likely to 
show high titer TE -ADA, a high titer was not predictive of adverse events ( AEs). 
Currently, Phase 3 Study I5T -MC-AACI in early symptomatic AD, Phase 2 
Study  I5T-MC-AACH in symptomatic AD, and Phase 3 Study I5T -MC-AACM in cognitively 
unimpaired participants wi th evidence of AD pathology  are ongoing.  
A detailed description of the chemistry , pharmacology, efficacy, and safety of donanemab  is 
provided in the IB. 
2.3. Benefit/Risk Assessment   
The following are the risks and discomforts associated with donanemab:  
 ARIA  
 TE-ADAs  
 IRR and , 
 hypersensitivity.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
17 Amyloid -related imaging abnormalities  have been observed in patients with MCI or AD in 
completed Phase  1 studies, AACD and AACC, Phase  2 study AACG, and in the ongoing Phase  3 
studies. Events of ARIA may be serious, or life threatening and could lead to permanent 
disability or death.  
Incidences of ARIA -E occur spontaneously at rates of 0.1 % to 1%. Incidences of ARIA -H occur 
spontaneously at rates  of 10 % to 20% (Ketter  et al. 2017). Both spontaneously occur more 
frequently in apolipoprotein E genotype ε4 (ApoE4)  carriers than noncarriers, and ARIA -E is a 
risk factor for the occurrence of ARIA -H. Both ARIA -E and ARIA -H occur more frequently 
with ant ibody therapies directed at amyloid and are considered a class effect. Other anti -amyloid 
antibodies in clinical development have demonstrated a dose -dependent risk for ARIA -E. Most 
of these cases are asymptomatic and have been detected by routine brain magnetic resonance 
imaging . When symptoms are present in association with these imaging abnormalities, they have 
been reported to  include headache, vomiting, unsteadiness, dizziness, tremor, confusion, visual 
disturbances, speech disturbances, worsening cogn itive function, alteration of consciousness, and 
seizures ( Ostrowitzki  et al. 2012; Sperling  et al. 2012; VandeVrede  et al. 2020; 
Mintun  et al. 2021; Swanson  et al. 2021 ). In most cases, these imaging abnormalities have not 
required treatment other than di scontinuation of the investigational compound, typically resulting 
in resolution of imaging abnormalities. Infrequently, high -dose steroid therapy has been 
administered in the presence of prominent symptoms.  
In this study (Study AACP), ARIA -E and ARIA -H ev ents are not expected given the young 
healthy population being enrolled. These participants are expected to not have amyloid deposits 
in their brain and thus the risk of ARIA -E and ARIA -H is considered low.  
Treatment emergent -ADAs and IRRs have been obser ved in studies, AACC, AACD, and 
AACG . 
All biological agents carry the risk of systemic allergic/hypersensitivity reactions and patients 
should be monitored for the occurrence of these reactions. Clinical manifestations of these 
reactions may include but ar e not limited to the following:  
 skin rash  
 pruritus (itching)  
 dyspnea  
 urticaria (hives)  
 angioedema ( eg, swelling of the lips and/or tongue)  
 hypotension , and  
 anaphylactic reaction . 
See IB Section 6.2.2.7 for more information regarding frequency of hypersensi tivity reactions . 
There were no hypersensitivity reactions  in healthy participant s in Study AACC . 
Treatment emergent -ADAs have been observed after a single dose of donanemab across all dose 
levels assessed and including the single cohort of healthy participants in the Study  AACC. 
Therefore, TE -ADAs will be carefully monitored in this study.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
18 There is no anticipated therapeutic benefit for the healthy participants in this study . However, 
participants may benefit from the screening procedures (through detection of unknown health 
issues) even if they receive no therapeutic benefit from the study . 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of donanemab  may be found in the IB. 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
19 3. Objectives  and Endpoi nts  
Objectives  Endpoints  
Primary   
 To characterize the PK profile of 
donanemab following administration 
of 350 mg IV doses in healthy 
participants   AUC 0-4Weeks   
 Cmax,ss , and  
 AUC,ss  
Secondary   
 To investigate the safety and 
tolerability of donanemab following 
administration of 350 mg IV doses in 
healthy participants   Incidence of treatment -emergent 
adverse events and serious adverse 
events  
Exploratory   
 To assess the effect of TE -ADAs on 
the PK of 350 mg IV donanemab   
 
 
 
 To characterize immunogenicity of 
donanemab following administration 
of 350 mg IV doses in healthy 
participants   Model parameters for the 
exposure -response relationship 
between donanemab serum  
concentrations a nd ADA titer   
 
 Incidence of TE-ADA  
Abbreviations: ADA  = anti-drug antibody; AUC,ss = area under the concentration versus time curve during a 
dosing interval at steady state ; AUC 0-4Weeks = area under the concentration versus time curve  0 to 4 weeks ; 
Cmax,ss = maximum observed drug concentration  during a dosing interval at steady state ; IV = intravenous; 
PK = pharmacokinetic ; TE-ADA = treatment -emergent anti -drug antibodies.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
20 4. Study Design   
4.1. Overall  Design   
This is a Phase 1, open -label study to evaluate the  PK, safety, and tolerability of 350 mg 
donanemab administered as a  single IV dose Q2W for 10 weeks  in healthy participants. 
Approximately  40 participants may be enrolled so that approximately 25  participants complete 
the study. Participants will receive a single 350  mg dose of IV donanemab  Q2W  for 1 0 weeks. 
After each dose administration, participants will remain in the clinical research unit (CRU) for 
up to 5  days. Participants will return to the CRU for regular outpatient visits until the next dose 
of donanemab. These visits will occur on Days 3, 4, 5 , and 8 (unless the participant is still 
admitted t o the CRU, in which activities for those days will be performed during the inpatient 
stay). After the last dose of donanemab, participants will return for outpatient visits up to 
12 weeks after the last dose.  
Screening may occur up to 28 days prior to enr ollment into the study. Once the informed consent 
is signed by the participants, they will be assessed for eligibility and will undergo screening 
procedures outlined in the Schedule of Activities  (SoA; Section  1.3). 
Participant s who are not enrolled within 28  days of screening may undergo an additional medical 
assessment and/or clinical measurements to confirm their eligibility. Eligible participants  will be 
admitted to the CRU on Day -1 prior to dosing in each of the 6  treatment periods. On Day 1 of 
each treatment period, participants will be dosed with an IV dose of donanemab and remain in 
the CRU until discharge on Day 2, although participants may remain inpatient up to Day 5 of 
each treatment period at the discretion of the investigator. After dosing with 350 mg donanemab, 
participants  will return to the CRU approximately 2 weeks later to be admitted at Day  -1 of the 
subsequent period.  
Safety and tolerability will be assessed through electrocardiograms ( ECGs ), clinical laboratory 
tests, vital sign measurements, recording of AEs, physical examination , and neurological 
examination. Additionally, immunogenicity will be assessed.  
After disch arge from  the CRU after the final treatment period, participants will return for further 
outpatient assessments (safety, PK , and immunogenicity) until 12 weeks after the final dose.  
4.2. Scientific Rationale for Study Design   
Blinding  
The study will be open label as the primary outcome is PK. Therefore , placebo treatment is not 
required. Although safety and tolerability is a secondary objective, the safety profile of 
donanemab is well understood and at higher doses than that administered in this study.  
Pharmacokinetic sampling  
Pharmacokinetic  sampling time points have been selected to allow evaluation of PK sufficient to 
fulfill the study objectives.  
Study Population  
Healthy participants have been selected for this study as it has been demonstrated previously that 
the PK profile of donanemab is comparable between healthy participant s and AD patients. In 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
21 addition, there are no patient -centric outcomes in this study so a healthy participant population is 
considered appropriate.  
4.3. Justification for Dose   
Donanem ab 350 mg  IV Q2W was selected for this study because  this dose is within the dose 
range previously evaluated in Phase 1 and Phase 2 studies . A 350 mg dose of donanemab  
administered as a single IV dose is within the dose range previously evaluated in Phase  1 studies 
(Studies  AACC and AACD) . In Study AACC, doses of 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 
and 10  mg/kg (equivalent to approximately 7 mg, 21  mg, 70 mg, 210 mg, and 700  mg, 
respectively ) of donanemab were assessed. Doses at or below 3 mg/kg (210 mg) had lower than 
dose proportional exposure (with half-life ~ 4.7 days ) whereas  exposure following the single 
doses of donanemab between 10  mg/kg (700 mg) and 40  mg/kg (2800 mg) w ere shown to b e 
dose proportional (with half -life of 11 days) in Study  AACD.  
Observed exposure following a 350-mg dose of  donanemab from  this study will assess whether 
this exposure falls within linear or nonlinear exposure range  compared with a 700- to 2800 -mg 
dose ra nge. 
In participants with MCI due to AD or mild to moderate AD , including Japanese and 
non-Japanese, the following doses were generally well tolerated:  
 up to 40 mg/kg , that is approximately 2800 mg  as a single dose , and 
 up to 20 mg/kg , that is approximately 1400 mg as multiple doses administered Q4W.  
4.4. End of Study  Definition   
The end of the study is defined as the date of the last visit of the last participant in the study.  
A participant is considered to have completed the study if the participant  has completed all 
periods  of the study including the last visit . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
22 5. Study Population   
Eligibility of participants for enrollment in the study will be based on the results of screening 
medical history, physical examination, vital signs, clinical laboratory tests , and ECG. The nature 
of any conditions present at the time of the physical exami nation and any preexisting conditions 
will be documented.  
The inclusion and exclusion criteria used to determine eligibility should be applied at screening 
only unless otherwise specified, and not continuously throughout the trial.  
Screening may occur up to 28 days prior to enrollment. Participants who are not enrolled within 
28 days of screening may undergo an additional medical assessment and/or clinical 
measurements to confirm their eligibility.  
Prospective approval of protocol de viations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in th e study only if all of the following criteria apply:  
Age 
1. Participant must be 18 to 40  years of age inclusive, at the time of signing the informed 
consent.  
Type of Participant and Disease Characteristics  
2. Participants who are overtly healthy as determined by medical evaluation including 
medical history, physical examination, laboratory tests, vital signs, and card iac 
monitoring  
Weight  
3. Body mass index (BMI) within the range of 19.0 to 32.0 kg/m2 (inclusive).  
Sex and Contraceptive/Barrier Requirements  
4. Male or female  
Women of childbearing potential will be  excluded from the study.   
Contraceptive use by participants  should be consistent with local regulations regarding the 
methods of contraception for those par ticipating in clinical studies . For the contraception 
requirements of this protocol, see Appendix 10.4. 
Informed  Consent  
5. Capable of giving signed informed consent as described in Appendix 1  (Section 10.1), 
which includes compliance with the requirements and restrictions listed in the informed  
consent form (ICF) and in this protocol . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
23 Other Inclusions  
6. Clinical laboratory test results within normal reference range for the population or 
investigator site, or results with acceptable deviations that are judged to be not clinically 
significant by the  investigator.  
7. Venous access sufficient to allow IV drug delivery and blood sampling as per the 
protocol.  
8. Are reliable and willing to make themselves available for the duration of the study and 
are willing to follow study procedures and research unit polic ies. 
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
9. Have a h istory of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous 
malformation, carotid, carotid artery occlusion, stroke or epilepsy or family history of 
dementia or Down’s syndrome.  
10. Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, 
endocrine, hematological, immunological, or neurological disorders capable of 
significantly altering the absorption, metabolism, or elimination of drugs; o r constituting 
a risk when taking the study medication; or of interfering with the interpretation of dat a. 
11. Have allergies to either humanized monoclonal antibodies, diphenhydramine, 
epinephrine, or methylprednisolone . 
12. Have had gamma globulin therapy within the last 6 months.  
13. Have a h istory within the past 5 years of a primary or recurrent malignant disease.  
14. Have a history of clinically significant multiple or severe drug allergies or severe 
posttreatment hypersensitivity reactions (including but not limited to erythema 
multiforme major, linear immunoglobulin A  dermatosis, toxic epidermal necrolysis, 
exfoliati ve dermatitis).  
15. Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at 
significant risk for suicide . 
16. Have answered “yes” to either Question 4 or Question 5 on the “Suicidal Ideation” 
portion of the Columbia -Suicide Severi ty Rating Scale (C -SSRS) or have answered “yes” 
to any of the suicide -related behaviors on the “suicidal behavior” portion of the C -SSRS, 
and the ideation or behavior occurred within the past month.  
17. Have a history or presence of psychiatric disorders  consi dered to be clinically significant 
in the opinion of the investigator . 
18. Have evidence of human immunodeficiency virus (HIV) infection and/or positive HIV  
antibodies . 
19. Have spontaneously cleared hepatitis C virus (HCV) infection, defined as a positive HCV 
antibody test and a negative HCV RNA test. Participants with no history of HCV 
antibody (anti -HCV) treatment, may be eligible for inclusion in the study, provided they 
have no detectable HCV RNA at screening for this study.   
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
24 20. Have a current infection with hepatitis B virus (HBV ), that is, positive for hepatitis B 
surface antigen , polymerase chain reaction ( PCR ) positive for HBV DNA or both.  
21. Are lactating . 
Prior/Concomita nt Therapy  
22. Have used over -the-counter or prescription medications, including herbal medication, 
within 7 days prior to dosing.  
Prior/Concurrent Clinical Study Experience  
23. Are currently enrolled in, have completed or discontinued dosing within the last 30  days 
or 5 half -lives of investigational product from a clinical trial involving an investigational 
product; or are concurrently enrolled in any other type of medical research . 
24. Have previously completed or withdrawn from this study or any other study invest igating 
donanemab . 
Diagnostic Assessments  
25. Have s creening clinical laboratory test results with unacceptable deviations that are 
judged to be clinically significant by the investigator.  
26. Have a n abnormality in the 12 -lead ECG, abnormal blood pressure , and pu lse rate 
considered clinically significant by the investigator.  
Other Exclusions  
27. Are investigator site personnel directly affiliated with the study, or are immediate family 
of investigator site personnel directly affiliated with the study. Immediate family  is 
defined as a spouse, parent, child, or sibling, whether biological or legally adopted.  
28. Are Lilly employees or employees of third -party organizations involved with the study.  
29. Known history of alcohol or drug abuse (as defined by the Diagnostic and Statistical 
Manual, fifth Edition, Text Revision) within 2 years prior to enrolling or a positive result 
regarding use of illicit drugs on the drug screening test.  
30. Have an average weekly alcohol intake that exceeds 21 units for males and 14 units for 
femal es per week, or are unwilling to stop alcohol consumption [from 24 hours prior to 
dosing  until leaving the CRU] (1 unit = 12 oz or 360 mL of beer; 5 oz or 150  mL of wine; 
1.5 oz or 45 mL of distilled spirits) . 
31. Have donated blood of more than 400 mL within the last 3 months, or any blood donation 
(including apheresis) within the last 1 month, or total volume of blood donation within 
12 months is 1200 mL at screening.  
32. In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.  
33. Are pregnant or  intend to become pregnant or to breastfeed during the study . 
34. Smoke more than 10 cigarettes per day or are unable to abide by investigative site 
smoking restrictions . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
25 5.3. Lifestyle Considerations   
5.3.1.  Meals and Dietary Restrictions   
 Standard meals will be provided at all times while participants are resident at the CRU, as 
per the CRU’s policy .  
5.3.2.  Subst ance Use: Caffeine, Alcohol, and Tobacco   
 During each dosing session, participant s will abstain from ingesting caffeine - or 
xanthine -containing products ( eg, coffee, tea, cola drinks , and chocolate) for 24 hours 
before the start of dosing until after collection o f the final PK and/or pharmacodynamic 
sample . 
 During each dosing session, participant s will abstain from alcohol for 24 hours before  the 
start of dosi ng until leaving the CRU . 
 Participant s who use tobacco products will be instructed that use of nicotine -containing 
products (including nicotine patches) will not be permitted while they are in the clinical 
unit.  
5.3.3.  Activity   
Participant s will abstain from strenuous exercise for 24 hours  before each blood collection for 
clinical laboratory tests.  Participant s may participate in light recreational act ivities during studies 
(eg, watch ing television, read ing). 
5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study .  
Individuals who do not meet the criteria for participation in this study (screen failure) may not  be 
rescreened. If applicable, participants may be re -tested at the discretion of the investigator ( eg, 
abnormal laborator y result) before being deemed a screen failure .   
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention of 
a Participant   
Not applicable.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
26 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  
6.1. Study Intervention(s) Administered   
This table lists the interventions used in this cl inical study.  
Intervention Name  Donanemab  
Dosage Level(s)  350 mg Q2W  
Route of Administration  IV infusion  
Abbreviations: IV = intravenous ; Q2W = every 2 weeks.  
Packaging and labeling  
Study intervention s will be supplied by the sponsor in accordance with current Good 
Manufacturing Practice. Study interventions  will be labeled as appropriate for country 
requirements .  
6.1.1.  Administration Details   
Donanemab will be administered as slow IV infusion over at least 30  minutes. Resuscitation 
equipment, emergency drugs, and appropriately trained staff must be available during the 
infusion and for at least 4 hours after participants have completed their infusion.  
6.1.1.1.  Management  of Infusion Reactions   
There is a risk of infusion reaction with any biological agent; therefore, all participants should be 
monitored closely. Symptoms and signs that may occur as part of an infusion reaction include, 
but are not limited to:   
 fever 
 chills  
 nausea  
 headache  
 bronchospasm  
 hypotension  
 angioedema  
 throat irritation  
 rash 
 pruritus  
 myalgia, and  
 dizziness.   
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
27 In the event that a significant infusion reaction occurs, the fol lowing guidance should be 
followed:  
 The investigational product infusion should be slowed ( eg, reduce infusion rate by 50% 
[eg, an infusion rate of 12 mL/h becomes 6 mL/h or slower]) or stopped, depending on 
the symptoms/signs present:  
o if slowed, the inf usion should be completed at the slower rate, as tolerated  
o if determined by the investigator that the infusion should no longer continue, no 
further attempts to dose the participant should be made  
 Supportive care should be employed in accordance with the  symptoms/signs  
If a participant ’s infusion reaction is sufficiently severe to discontinue the infusion, subsequent 
infusions may be administered with premedication at the discretion of the investigator following 
agreement with the Lilly clinical research physician (CRP ) or clinical pharmacologist .  
If a participant ’s infusion rate is reduced due to an infusion reaction, subsequent infusions may 
be administered at the discretion of the investigator following agreement with the Lilly CRP or  
clinical pharmacologist. If further infusions are administered, the infusion rate must not exceed 
the slowest rate used to complete the infusion on the occasion the infusion reaction occurred. 
Premedication may be administered at the discretion of the inv estigator . 
If it is determined the participant should not receive further doses of investigational product, the 
participant should complete AE and other follow -up procedures per Section  1.3 of this protocol.  
6.2. Preparation , Handling , Storage , and Accountability   
1. The investigator or designee must confirm appropriate storage  conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention . Only authorized  
study personnel  may supply , prepare,  or administer study intervention. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
3. The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and 
final disposition records).  
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Pharmacy Manual . 
6.3. Assignment to Study Intervention   
This is a n open -label study with only 1 treatment.  
6.4. Blinding   
Not applicable as this is an open -label study  with only 1 treatment . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
28 6.5. Study Intervention Compliance   
Study intervention will be administered under medical supervision by the investigator or 
designee. The dose of donanemab  and study participant identification will be confirmed p rior to 
the time of dosing. The date and time of each dose administered will be recorded in the source 
documents and in the case report form (CRF ). 
6.6. Dose Modification   
Dose adjustm ents are not permitted  in this study . 
6.7. Continued Access to Study Intervention after the End of the Study   
Not applicable.  
6.8. Treatment of Overdose   
In the event of an overdose, the investigato r or treating physician should:  
 contact the medical monitor immediately  
 closely monitor the participant for any AE/  serious adverse event (SAE ) and 
laboratory abnormalities , and  
 obtain a plasma sample for PK analysis if requested by the medical monitor 
(determined on a case -by-case basis).   
6.9. Prior and Concomitant Therapy   
Any medication (including over -the-counter or prescription medicines, vitamins, and/or herbal 
supplements) or other specific categories of interest that the participant is receiving at the time of 
enrollment or receives during the study must be recorded along with:  
 reason for use  
 dates of administration including start and end dates , and  
 dosage information including dose and frequency for concomitant therapy of 
special interest . 
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
Participants must abstain from taking prescription or nonprescription drugs (including vitamins 
and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever  is longer) before the start of study intervention until 
completion of the follow -up visit , unless , in the opinion of the investigator and sponsor, the 
medication will not interfere with the study.  
Acetaminophen , at doses of 3 grams/day , is permitted for use in a 24 -hour period  at the 
discretion of the investigator.  Other concomitant medication may be considered on a 
case-by-case basis by the investigator in consultation with the  medical monitor if required . Any 
additional medication used during the course  of the study must be documented.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
29 COVID -19 Considerations  
Government guidance for Health Facilities should be followed when conducting visits.  
The use of a severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus  
(SARS -CoV -2) vaccine i n participants treated with donanemab has not been studied by Lilly. 
However, g iven the risk posed by  coronavirus disease 2019  (COVID -19) in the midst of this 
pandemic , decisions regarding the use of any vaccination, including approved/authorized for use 
vaccines, in participants treated with donanemab should be made at the discretion of the treating 
physician using their best clinical judgment and after careful considera tion of risk benefit factors 
for the participant. If you have any questions regarding the type of vaccine that can be used for 
your clinical study participants, please contact your Centers for Disease Control and Prevention 
(CDC ) or medical monitor for fur ther instructions. Please have information on the vaccine(s) 
available in your country, prior to contacting your medical monitor.  
Please consult the vaccine product label for further information regarding associated risks and 
precautions, and guidance fro m your local regulatory agency. Hypersensitivity events have been 
reported in association with certain vaccines, in close temporal relation to the application. Taking 
this into consideration, it is recommended that study drug not be administered sooner tha n 5 days 
before or after a vaccination.  
As with all other concomitant medications , please ensure you record applicable information 
regarding an individual ’s receipt of vaccination(s) in the participant ’s source documents, and 
then follow the CRF instructi ons for concomitant medications for appropriate capture of vaccine 
administration in the CRFs. Please record each administration date of the vaccine (each time) as 
a concomitant medication in the CRF. If the participant is vaccinated outside of your facili ty, 
please request and record information such as manufacturer and dose date, when available. Any 
possible related AEs from the vaccination should be reported according to the Lilly Adverse 
Event/Seri ous Adverse Event reporting guidance and to the appropri ate manufacture, according 
to local practice.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
30 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal   
Participants discontinuing from the study premature ly for any reason must complete AE and 
follow -up procedures per Section  1.3 of this protocol.  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1  
(Section  10.1).  
7.1. Discontinuation of Study Intervention   
When  necessary , a participant  may be permanently discontinue d from  study intervention . If so, 
the pa rticipant  will remain in the study and follow procedures for remaining study visits , as 
shown in the SoA . A participant should be permanently discontinued  from study intervention if  
 the participant becomes pregnant during the study,  
 in the opinion of the investigator, the participant should permanently discontinue the 
study intervention for safety reasons  
 if the investigator determines that a systemic hypersensitivity reaction has occurred 
related to study intervention administration, the participant may be permanently 
discontinued from the study intervention, and the sponsor’s designated medical monitor 
shoul d be notified. If the investigator is uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of study intervention 
is warranted, the investigator may consult the sponsor . 
In addition, study drug may be discont inued if participants  
 answered “yes” to Question 4 or Question 5 on the “Suicidal Ideation ” portion of the 
C-SSRS, or  
 answered “yes” to any of the suicide -related behaviors on the Suicidal Behavior portion 
of the C -SSRS.  
A psychiatrist or appropriately tra ined professional may assist in the decision to discontinue the 
participant.  
7.1.1.  Liver Chemistry Stopping Criteria   
Discontinuation of the study intervention for abnormal liver tests  should be considered  by the 
investigator when a participant meets 1 of the following conditions after consultation with the 
Lilly designated medical monitor:   
 ALT (alanine aminotransferase ) or AST (aspartate aminotransferase) >5 × for healthy 
participants  upper limit of normal  (ULN)  
 ALT or AST >3 × ULN for healthy participants  sustained for more than 2 weeks or   
 ALT or AST >3 × ULN and total bilirubin level (TBL) >2 × ULN or international 
normalized ratio  (INR) >1.5 or   
 ALT or AST >3 × ULN the appearance of fat igue, nausea, vomiting, right upper -quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)   
 alkaline phosphatase  (ALP ) >3× ULN   
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
31  ALP >2.5 × ULN and TBL >2 × ULN   
 ALP >2.5 ULN with the appearance of fatigue, nausea, vomiting, right quadrant pain o r 
tenderness, fever, rash, and/or eosinophilia (>5%) .  
Participants who discontinue from study intervention due to the abnormal liver tests will undergo 
monitoring as described in Appendix 10.6.  
Interrupting study drug based on liver test elevations in participants with normal or 
near -normal baseline liver tests  
In study participants with normal or near normal baseline liver tests (ALT, AST, ALP <1.5 × 
ULN), the study drug  should be interrupted  and close hepatic monitoring initiate d (see 
Section  8.2.8.1 ) if one or more of thes e conditions occur:  
Elevation  Exception  
ALT or AST >5 × ULN   
ALT or AST >3 × ULN and either TBL >2 × ULN or INR >1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for  drug interruption decisions rather 
than TBL>2 × ULN.  
ALT or AST >3 × ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3 ×ULN, when the source of increased ALP is the  liver  
ALP >2.5 × ULN and TBL >2 × ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2× ULN.  
ALP >2.5 × ULN with the  appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Abbreviation s: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio ; TBL = total bilirubin; ULN = upper limit of normal.   
Source: [FDA] United States Food and Drug Administration . Drug -induced liver injury: premarketing clinical 
evaluation : guidance for industry.  July 2009 . Accessed August 26, 20 22. 
https://www.fda.gov/media/116737/download  
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
32 Interrupting study drug based on elevated liver tests in participants with abnormal 
baseline liver tests  
In study participants with abnormal baseline liver tests (ALT, AST, ALP ≥1.5 × ULN), the study 
drug should be  interrupted  if one or more of these conditions occur:  
Elevation  Exception  
ALT or AST >3 × baseline   
ALT or AST >2 × baseline and either TBL >2 × ULN or INR 
>1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then do ubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL>2 × ULN.  
ALT or AST >2 × baseline with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (>5%)   
ALP >2.5 × baseline, when the source of increased ALP is the 
liver  
ALP >2 × baseline and TBL >2 × ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interrupti on decisions rather 
than TBL>2 × ULN.  
ALP >2 × baseline with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = total bilirubin; ULN = upper limit of normal.  
Source: [FDA] United States Food and Drug Administration . Drug -induced liver injury: premarketing clinical 
evaluation : guidance for industry.  July 2009 . Accessed August 26, 2022.  
https://www.fda.gov/media/116737/download  
Resuming study drug after elevated liver tests  
Resumption of the study drug can be consider ed only in consultation with the Lilly -designated 
medical monitor and only if the liver test results return to baseline and if a self -limited nondrug 
etiology is identified. Otherwise, the study drug should be discontinued.  
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study : 
 at any time at the participant’s  own request  
 at the request of the participant’s  designee ( eg, parents or legal guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or administrative 
reasons  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
33  if enrolled  in any other clinical study involving an investigational product , or enrolled  in 
any ot her type of medical research judged not to be scientifically or medically compatible 
with this study  
 if the participant , for any reason, requires treatment with a therapeutic agent that is 
prohibited by the protocol and has been demonstrated to be effectiv e for treatment of the 
study indication . In this case , discontinuation from the study occurs prior to introduction 
of the new agent . 
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinua tion visit , as shown in the S oA. If the participant has not already 
discontinued the study intervention, the participant will be permanently discontinued from the 
study intervention at the time of the decision to discontinue the study.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, the participant  may request destruction of any samples ta ken and not 
tested , and the investigator must document this in the site study records .  
7.3. Lost to Follow  up  
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. Site personnel or designee are 
expected to make diligent attempts to contact participants who f ail to return for a scheduled visit 
or were otherwise unable to be followed up by the site.   
Site personnel, or an independent third party, will attempt to collect the vital status of the 
participant within legal and ethical boundaries for all participants  randomized, including those 
who did not get investigational product. Public sources may be searched for vital status 
information. If vital status is determined  to be deceased , this will be documented and the 
participant will not be considered lost to follow -up. Sponsor personnel will not be involved in 
any attempts to collect vital status information .  
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
34 8. Study Assessments and Procedures   
 Study procedures and their timing are su mmarized in the SoA.   
 Immediate  safety concerns  should be discussed with the s ponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
 Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct.  
 All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log  to record details of all participant s screened and to confirm 
eligibility or record reasons for sc reening failure, as applicable .  
 Section  1.3 lists the SoA, detailing the study procedures and their timing 
(including tolerance limits for timing). The specifications in this protocol for the 
timings of safety and sample collection are given as targets to be achieved within 
reasonable limits. Modifications may be made to the time points based upon 
emerging clinical information. The scheduled time points may be subject to minor 
alterations; however, the actual time must be correctly recorded.  
 Appendix 10.2 lists the laboratory tests that will be performed for this study.  
 Appendix 10.2.1  provides a summary of the maximum number and volume of 
invasive samples, for all sampling, during the study.  
 Unless otherwise stated in subsections below, all samples collected for specified 
laboratory tests will be destroyed within 60 days of receipt o f confirmed test 
results. Certain samples may be retained for a longer period, if necessary, to 
comply with applicable laws, regulations, or laboratory certification standards.  
8.1. Efficacy Assessments   
Not applicable.  
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in t he SoA.  
8.2.1.  Physical Examinations   
 A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal , and neurological  syste ms. Height and 
weight will also be measured and recorded.  
 Symptom -directed physical assessment may be conducted at other visits as 
mentioned in SoA and as clinically indicated. Symptom -directed physical 
examinations may also be conducted at other visits, a s determined by the 
investigator, if a participant presents with complaints.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
35  Investigators should pay special attention to clinical signs related to previous 
serious illnesses.  
8.2.2.  Vital Signs   
 For each participant , vital s igns measurements should be conducted according to 
the S oA (Section  1.3). 
 Additional vital signs may be measured during the study if warranted.  
 Blood pressure and pulse rate should be measured after at least 5 minutes supine.  
 Unscheduled orthostatic vital signs s hould be assessed if possible, during any AE 
of dizziness or posture -induced symptoms. If orthostatic measurements are 
required, participants should be supine for at least 5 minutes and stand for at least 
3 minutes. If the participant feels unable to stand , only the supine vital signs will 
be recorded.  
 Body temperature should be measured as indicated in the SoA, or any time that it 
is clinically indicated.  
8.2.3.  Electrocardiograms   
 Single 12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) 
using an ECG machine that automatically calculates the heart rate and measures 
PR, QRS, QT, and corrected QT interval (QTc).  
 For each participant, ECGs should be collected according to the SoA 
(Section  1.3). 
 Any clinically significant findings from ECGs that result in a diagnosis and that 
occur after the participant receives the first dose of the investigational product, 
should be reported to Lilly, or its designee, as an AE via  the eCRF . 
 Electrocardiograms must be recorded before collecting any blood samples. 
Participants must be supine for approximately 5 to 10  minutes before ECG 
collection and remain supine but awake during ECG collection. 
Electrocardiograms may be obtained at additional times, when deemed clinically 
necessary. All ECGs recorded should be stored at the investigational site.  
 Electrocardiograms will be interpreted by a qualified physician (the investigator 
or qualified designee) as soon after the time of ECG collection as possible, and 
ideally while the participant is still present, to determine whether the participant 
meets entry criteria at the relevant visit(s) and fo r immediate participant 
management, should any clinically relevant findings be identified.  
8.2.4.  Clinical Safety Laboratory Tests   
 See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be 
performed and the So A for the timing and frequency.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
36  The investigator must review the laboratory results , document this review, and 
report  any clinically relevant changes occurring during the study as an AE . The 
laboratory results must be retained with source documents unless a Source 
Documen t Agreement or comparable document cites an electronic location tha t 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by the investigator to be more severe than expected for the 
participant's cond ition.  
 All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within the follow -up period after the last dose 
of study intervention should be repeated until the values return to normal or 
baseline  or are no longer considered clinically significant by the investigator or 
medical monitor.  
○ If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified and the 
sponsor n otified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2  
(Section 10.2), must be conducted in accordance with the SoA , standard 
collection requirements , and laboratory manual . 
 If laboratory values from non -protocol specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant management or are considered clinically significant by the investigator 
(eg, SAE or AE or dose modification), then  report the information as an AE .  
8.2.5.  Pregnancy Testing   
Pregnancy testing will be performed as specified in  the SoA . 
8.2.6.  Neurological Examination   
A neurological examination will be performed by the investigator (or designee) at the time points 
specified in the SoA. If clinically significa nt abnormalities are noted at these time points, 
additional examinations should be performed as clinically necessary. The examiner should be 
familiar with the participant’s baseline examination. Elements of the examination may include 
inspection for tremor s, extraocular movements, brachial and patellar deep tendon reflexes, 
finger -nose pointing, and Romberg sign.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
37 The table below presents the scoring of the neurological examination findings.  
Score  0 1 2 3 4 
Tremor  Absent  Visible with limb 
extension and/or 
careful inspection  Visible without 
limb extension  Interferes with 
motor function   
Nystagmus  Absent  1 to 3 beats on 
lateral gaze  >3 beats on 
lateral gaze  Present on 
forward gaze   
Reflexes (brachial or patellar)  Normal  Trace  Absent  Increased  Clonic  
Finger -nose Normal  Abnormal     
Romberg sign  Absent  Present     
 
8.2.7.  Suicidal Ideation and Behavior Risk Monitoring   
C-SSRS  
Columbia -Suicide  Severity Rating Scale is a scale that captures the occurrence, severity, and 
frequency of suicidal ideation and behavior during the assessment period via a questionnaire. 
The scale was developed by the National Institute of Mental Health  trial group  for the purpose of 
being counterpart to the Columbia Classification Algorithm of Suicide Assessment 
categorization of suicidal events. The C -SSRS will be performed by the investigator (or 
designee) at the time points specified in the SoA.  
Donan emab  is considered to be a central nervous system -active  drug.  Participants  being treated 
with donan emab should be monitored appropriately and observed closely for suicidal ideation 
and behavior (SIB) or any other unusual changes in behavior, especially at the beginning and end 
of the course of intervention , or at the time of dose changes, either increases or decreases. 
Participants who experience signs of SIB should undergo a risk assessment. All factors 
contributing to SIB should be evaluated and consideration should be given to discontinuation of 
the study in tervention .  
In the clinical trials with donanemab to date, there  has been no association between don anemab 
treatment and  suicidal ideation.  
When informed consent or assent has been given, families and caregivers of participants  being 
treated with donanema b should be alerted about the need to monitor participants  for the 
emergence of unusual changes in behavior, as well as the emergence of suicidal ideation and 
behavior and to report such symptoms immediately to the study investigator.  
Baseline assessment of suicidal ideation and intervention emergent suicidal ideation and 
behavior  will be monitored during Study AACP  using  the C-SSRS . 
8.2.8.  Safety Monitoring   
The Lilly clinical pharmacol ogist or CRP/scientist will monitor safety data throughout the course 
of the study.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
38 Lilly will review SAEs within time frames mandated by company procedures. The Lilly clinical 
pharmacologist or CRP will periodically review  
 trends in safety data  
 laboratory analytes   
 AEs, including monitoring of incidence of any nature of any neurological symptoms, 
infusion related reaction, and allergic or hypersensitivity reactions,  
 ECGs,  
 neurological examinations, and  
 physical examinations .  
When appropriate, t he Lilly clinical pharmacologist or CRP will consult with the functionally 
independent Global Patient Safety therapeutic area physician or clinical research scientist.  
8.2.8.1.  Hepatic Safety   
Close hepatic monitoring  
Laboratory tests (Appendix 6 [Section  10.6]), including ALT, AST, ALP, TBL, direct bilirubin, 
gamma -glutamyl transfera se, and creatine kinase  should be repeated within 48 to 72  hours to 
confirm the abnormality and to determine if it is increasing or decreasing, if one or more of these 
conditions occur:  
If a participant with baseline results 
of...  develops the following e levations:  
ALT or AST <1.5 × ULN  ALT or AST ≥3 × ULN  
ALP <1.5 × ULN  ALP ≥2 × ULN  
TBL <1.5 × ULN  TBL ≥2 × ULN (except for patients with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5 × ULN  ALT or AST ≥2 × baseline  
ALP ≥1.5 × ULN  ALP ≥2 × baseline  
TBL ≥1.5 × ULN  TBL ≥1.5 × baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviation s: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal.  
 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by the investigator in consultation with 
the Lilly -designated medical monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses ( eg, heart 
failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counte r), herbal and dietary supplements, and history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condit ion and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
39 participant’s clinical condition and lab results stabilize.  Monitoring of ALT, AST, ALP, and 
TBL should continue until levels nor malize or return to approximate baseline levels.  
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5 × ULN  ALT or AST ≥3 × ULN with hepatic signs/symptoms a, or  
ALT or AST ≥5 × ULN  
ALP <1.5 × ULN  ALP ≥3 × ULN  
TBL <1.5 × ULN  TBL ≥2 × ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5 × ULN  ALT or AST ≥2 × baseline with hepatic signs/symptoms a, or 
ALT or AST ≥3 × baseline  
ALP ≥1.5 × ULN  ALP ≥2 × baseline  
TBL ≥1.5 × ULN  TBL ≥2 × baseline (except for patients with Gilbert’s syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal.  
a Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/or eosinophilia >5%.  
 
At a minimum,  this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalized ratio 
(PT-INR); tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an abdominal 
imaging study ( eg, ultrasound or computed tomography scan).  
Based on the patient ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminop hen protein adducts, 
urine toxicology screen, Wilson ’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator ’s assessment of the 
participant ’s clinical condition, the invest igator should consider referring the participant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.   
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
40 Additional hep atic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
 Elevation of serum ALT to ≥5× ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 × ULN)  
o In participants with baseline ALT ≥1.5 × ULN, the threshold is ALT ≥3 × baseline 
on 2 or more consecutive tests  
 Elevated TBL to ≥ 2x ULN (if baseline TBL <1.5 × ULN) (except for cases of known 
Gilbert ’s syndrome)  
o In participants with baseline TBL ≥1.5 × ULN, the threshold should be TBL ≥2 × 
baseline  
 Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5 × ULN)  
o In participants with baseline ALP ≥1.5 × ULN, the threshold is ALP ≥2 × baseline 
on 2 or more consecutive blood tests  
 Hepatic event considered to be a n SAE  
 Discontinuation of study drug due to a hepatic event  
Note: the interval between the two consecutive blood tests should be at least 2 days.  
8.2.8.2.  Hypersensitivity  Reactions  Including Infusion Related Reactions   
Many drugs, including oral agents and biologic agents, carry the risk of sy stemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
Hypersensitivity, Anaphylactic, and Infusion Related Reactions  CRF s. 
Locations where study participants are receiving investigational pro duct should have 
appropriately trained medical staff and appropriate medical equipment  and rescue medications 
available . It is recommended that participants who experience a systemic hypersensitivity 
reaction be treated per the local standard  of care.  
If a participant experiences a  systemic hypersensitivity reaction or infusion related reaction either 
involving two or more organ systems (eg , mucocutaneous, respiratory, cardiovascular, or 
gastrointestinal systems), or that is severe , additional blood and urine samples should be 
collected as close to the event as possible, as described in Appendix 2  (Section  10.2.2 ). Tryptase 
and when applicable urine N -methylhistamine should be repeated in approximately 4 weeks to 
obtain postevent baseline.  Laboratory results are provided to the sponsor via the central 
laboratory . 
8.2.8.3.  Dosing Rechallenge and Premedication for Infusions   
Premedication for dosing is not planned. Dosing rechallenge is contraindicated in participants 
that have experienced a suspected or possible anaphylactic reaction (eg , reaction involving 2 or 
more organ systems  [eg, mucocutaneous, respiratory, cardiovascular, or gastrointestinal systems] 
occurring in close proximity to dosing), in a prior dose (Sampson et al . 2006). For infusion 
related reactions which are not suspicious for anaphylaxis, after review of the data , and at the 
investigator’s discretion, the participant may be rechallenged. If rechallenge is planned, the 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
41 participant may be premedicated for subsequent doses at the investigator discretion and 
according to local practice guidelines. Prior to initiating premedication, the investigator may 
consult with the sponsor. Any premedication given will be documented as a concomitant 
therapy . 
8.3. Adverse Events , Serious Adverse Events , and Product Complaints   
The definitions of the following events can be found in Appendix 3  (Section 10.3): 
 AEs 
 SAEs , and  
 Product complaints (PCs)  
These events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recordi ng events that meet the se definition s and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the  study  (see Section 7). 
Care will be taken not to introduce bias when detecting events . Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs will be followed  until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). For 
product  complaints, t he investigator is responsible for ensuring that follow -up includes any 
supplemental investigations as indicated to elucidate the nature and/or causality.  Further 
information on follow -up procedures is provided in Appendix 3 (Section  10.3).  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
42 8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanism for colle cting events.  
Event  Collection 
Start  Collection 
Stop  Timing  for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Adverse Event  
AE signing of 
the informed 
consent form 
(ICF)  participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  signing of 
the ICF  start of 
intervention  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAE  and SAE 
updates  – after 
start of study 
intervention  start of 
intervention  participation 
in study has 
ended  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAE a – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  60 days  
following the  
after final 
dose Within 24 hours (see 
Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
43 Event  Collection 
Start  Collection 
Stop  Timing  for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Product Complaints  
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  Product Complaint 
form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  Product Complaint 
form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed Product 
Complaint form 
with all changes 
signed and dated by 
the investigator  N/A 
PC (if 
investigator 
becomes aware)  Participation  
in study has 
ended  N/A Promptly  Product Complaint 
form   
Abbreviations: AE = adverse event; ICF = informed consent form; N/A = not applicable; PC = product complaints; 
SAE = serious adverse event.  
a Serious adverse events  should not be reported unless the  investigator deems them to be possibly related to study 
treatment  or study participation . 
 
Investigators are responsible for monitoring the safety of participants who have entered this 
study and for alerting Lilly or its designee to any event that seems unusual, even if this event 
may be considered an unanticipated benefit to the participant.  
The investigator is responsible for the appropriate medical care of participants during the study . 
8.3.1.1.  Adverse Event Monitoring with a Systematic Questionnaire   
Nonleading AE collection  should occur prior to the collection of the C -SSRS.  
If a suicide -related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collection, sites should not change the AE form.  
If an AE is serious or leads to discontinuation, it needs to be included on the AE form and the 
process for reporting SAEs is followed.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
44 8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
 The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive donanemab . 
 After learning of a pregnancy in the female partner of a study participant, the investigator 
will 
o obtain a consent  to release information  from the pregnant female partner directly, and 
o within 24 hours after obtaining this consent will record pregnancy information on the 
appropriate form and submit it to the sponsor .  
The female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the sponsor. 
Generally, the follow -up will be no long er than 6 to 8  weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of  gestational 
age, fetal status (presence or absence of anomalies) or indication for the procedure.  
Female participants who become pre gnant  
 The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial i nformation will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours  of 
learning of a participant's pregnancy.  
 The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Ge nerally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported , regardless of gestational age,  fetal status (presence or absence 
of anomalies) or indication for the pro cedure.  
 While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
 A spontaneous abortion (occurring at <2 0 weeks gestational age) or  still birth (occurring 
at ≥20 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
 Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor as described in protocol 
Section  8.3.1 . While the investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
45  Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study . If the participant is discontinued from the study, follow the 
standard discontinuation process and continue directly to the follow -up phase. The 
follow -up on the pregnancy outcome should continue independent o f intervention or 
study discontinuation . 
Prior to continuation of study intervention following pregnancy, the following must occur:  
 The sponsor and the relevant Institutional Review Board  (IRB)/Independent Ethics 
Committee ( IEC) give written approval . 
 The participant gives signed informed consent . 
 The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and the participant’s  offspring . 
8.4. Pharmacokinetics   
 Venous blood  samples of approximately 4 mL will be collected for measurement of 
serum  concentrations of donanemab  as specified in the SoA  (Section  1.3).  
 A maximum of 3 samples may be collected at additional time points during the study if 
warranted and agreed upon between the investigator and the sponsor.  The timing of 
sampling  may be altered during the course of the study based on newly available data 
(eg, to obtain data closer to the time of peak plasma concentrations) to ensure 
appropriate monitoring.  
 Instructions for the collection and handling of biological samples will be provided by 
the sponsor. The actual date and time (24 -hour clock time) of each sample will be 
recorded.  
8.5. Pharmacodynamics   
Pharmacodynamic parameters a re not evaluated in this study . 
8.6. Genetics   
A blood sample for DNA isolation will be collected from participants.  
See Appendix 5 (Section  10.5) for Information regarding genetic research  and Appendix 1 
(Section  10.1.11 ) for details about  sample retention and c ustody .  
8.7. Biomarkers   
Biomarkers are not evaluated in this study.  
8.8. Immunogenicity Assessments   
At the visits and times specified in the SoA  (Section  1.3), venous blood samples will be collected 
to determine antibody production against donanemab. Antibodies may be further characterized 
for their ability to neutralize the activity of donanemab.  To interpret the results of 
immunogenicity, a venous blood sample will be collected at the same time points to determine 
the serum concentrations of donanemab. All samples for immunogenicity should be taken 
predose when applicable and possible.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
46 Immunogen icity will be assessed by a validated assay designed to detect anti-drug antibodies 
(ADAs ) in the presence of donanemab at a laboratory approved by the sponsor.   
Treatment -emergent ADAs are defined in Section  9.3.6 . 
Samples will be retained for a maximum of 15 years after the last participant visit, if local 
regulations allow, at a facility selected by the sponsor. The  duration allows the sponsor to 
respond to future regulatory requests related to donanemab. Any  samples remaining after 
15 years will be destroyed.  
8.9. Health Economic s  
Health economics and health economics parameters are not evaluated in this study . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
47 9. Statistical Considerations   
The statistical analysis plan will be finalized prior to first participant first visit, and it will include  
a more technical and detailed description of the statistical analyses described in this section. This 
section is a summary of the planned statistical analyses of the most important endpoints , 
including primary and key secondary endpoints.  
9.1. Statistical Hypo theses   
Not applicable.  
9.1.1.  Multiplicity Adjustment   
Not applicable.  
9.2. Analyses  Sets  
The following populations are defined:  
Population  Description  
Entered  All participants who sign the informed consent form  
Pharmacokinetic  All enrolled participants who receive d at least 1 full dose of 
donanemab and  have baseline and at least one postbaseline 
evaluable pharmacokinetic sample.  Participants will be analyzed 
according to the intervention they actually  received.  
Safety  All participants randomly assigned to study intervention and who 
take at least  1 dose of study intervention. Participants will be 
analyzed according to the  intervention they actually received  
9.2.1.  Study Participant Disposition   
A detailed description of participant dis position will be provided at the end of the study.  
9.2.2.  Study Participant Characteristics   
Demographic and baseline characteristics will be su mmarized . 
9.3. Statistical Analyses   
9.3.1.  General Considerations   
Statistical analysis of this study will be the  responsibility of the Sponsor or its designee.  
Pharmacokinetic analyses will be conducted on data from all participants who receive at least 
1 dose of the investigational product and have evaluable PK data.  
Safety analyses will be conducted for all enroll ed participants who received study intervention, 
whether or not they completed all protocol requirements.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
48 Summary statistics, data tabulations, and data graphs will be provided as deemed appropriate.  
Additional exploratory analyses of the data will be con ducted as deemed appropriate. Study 
results may be pooled with the results of other studies for safety, immunogenicity, and 
population PK analysis purposes to avoid issues with post -hoc analyses and incomplete 
disclosures of analyses.  
Handling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and in the statistical analysis plan , where 
appropriate. Adjustments to the planned analyses are described in the final clinical study report .  
9.3.2.  Primary Endpoint Analyses : Pharmacokinetic Analyses   
9.3.2.1.  Pharmacokinetic Parameter Estimation   
Pharmaco kinetic parameter estimates for donanemab  will be calculated by standard 
noncompartmental methods of analysis.  
The primary parameters for analysis will be maximum drug concentration (C max,ss) and area 
under the concentration versus time curve 0 to 4 weeks  (AUC 0-4Weeks ) and during a dosing 
interval  at steady state  (AUC,ss) following multiple dosing  of donanemab . Other 
noncompartmental parameters, such as half -life, apparent clearance, and apparent volume of 
distribution may be reported.  
Noncompartmental a nalysis will be conducted, and PK parameter estimates of maximum 
observed drug concentration (C max), area under the concentration versus time curve from time  0 
to infinite time (AUC 0-∞), area under the concentration versus time curve from time  0 to last 
measured concentration (AUC 0-tlast), clearance and half -life will be reported for donanemab. 
Exposure ( AUC 0-4Weeks ) will be calculated. Other noncompartmental parameters may be 
reported, as appropriate.  
Exploratory graphical analyses relating donanemab serum exposure and immunogenicity may be 
conducted.  
9.3.3.  Secondary Endpoint(s) Analyses   
The incidence of TEAEs and SAEs to investigate the safety and  tolerability of donanemab 
followi ng IV administration of donanemab in healthy participants  Q2W  for 1 0 weeks at a 
350 mg dose  will be listed and/or summarized.   
9.3.4.  Exploratory Analyses   
The number of TEAEs will be re ported. The frequency and percentage of participants with 
preexisting ADAs and with TE -ADAs to donanemab will be tabulated.  The relationship between 
the presence of TE-ADAs  and serum donanemab concentration may be assessed .  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
49 9.3.5.  Safety Analyse s  
9.3.5.1.  Clinical Evaluation of Safety   
All investigational product and protocol procedure AEs will be listed , and if the frequency of 
events allows, safety data will be summarized using descriptive methodology.  
The incidence of AEs will be presented by severity and by association with investigational 
product as perceived by the investigator. Adverse events repo rted to occur prior to study entry 
will be distinguished from those reported as new or increased in severity during the study. Each 
AE will be classified by the most suitable term from the medical regulatory dictionary.  
9.3.5.2.  Statistical Evaluation of Safety   
All study intervention and protocol procedure AEs and SAEs will be listed, and if the frequency 
of events  allows, safety data will be summarized using descriptive methodology.  The i ncidence 
of symptoms will be presented by severity and by association  with the study intervention as 
perceived by the investigator. Symptoms reported to have occurred  prior to randomization will 
be distinguished from those reported as new or increased in s everity  during the study. Each 
symptom will be classified by the most suitable term from the Medical  Dictionary for Regulatory 
Activities.  The number of AEs and SAEs will be reported.   
Safety parameters that will be assessed include safety laboratory parameters, vital signs, and 
ECG parameters. The safety parameters will be listed and summarized using standard descriptive 
statistics. Additional analysis will be performed if warranted upo n review of the data.  
9.3.6.  Immunogenicity Assessments   
Treatment -emergent ADAs are defined as those with either  
 a titer 2 -fold (1 dilution) greater than the minimum required dilution i f no ADAs were 
detected at baseline (treatment -induced ADA) , or 
 those with a 4 -fold (2 dilutions) increase in titer compared to baseline if ADAs were 
detected at baseline (treatment -boosted ADA).  
The frequency of neutralizing antibodies may also be tabula ted in TE ADA+ participants , when 
available.  
The relationship between the presence of antibodies and the PK parameters and 
pharmacodynamic  response including safety and efficacy to donanemab  may be assessed.  
9.3.7.  Other Analyses   
Suicide -related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide.  
9.4. Interim Analys is  
No interim analyses are planned for this study. If an unplanned interim analysis is deemed 
necessary for reasons other than a safety concern, the protocol must be amended.   
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
50 Access to safety, PK , and immunogenicity data may occur on an ongoing basis throughout the 
study. The  purpose of these reviews is to inform the design of subsequent studies.  
9.5. Sample Size Determination   
Approximately  40 participants may be enrolled so that approximately 25 participants complete 
the study . The sample sizes described are customary for Phase 1 studies evaluating safety , PK, 
and immunogenicity  and is not powered on the basis of statistical hypothesis testing . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
51 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
● This study will be conducted in accordance wit h the protocol and with the following:  
○ Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
○ Applicable International Council for Ha rmonisation ( ICH) Good Clinical Practice 
(GCP) Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents ( for example , advertisements) must be submitted to an IRB/IEC by the 
investigator and reviewed and approved by the IRB/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes  necessary to eliminate an 
immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate 
hazard to study participants . 
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB /IEC  
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as required by 
IRB/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility and 
adherence to requirements of 21 C ode of Federal Regulations ( CFR), ICH guidelines, 
the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all 
other applicable local regulations  
○ Reporting to the sponsor or designee significant issues related to participant safety, 
participant rights, or  data integrity  
● Investigator sites are compensated for participation in the study  as detailed in the clinical 
trial agreement . 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
52 10.1.2.  Financial Disclosure   
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investi gators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process   
 The investigator or the investigator’s  representative will explain the nature of the study , 
including the risks and benefits,  to the participant or the participant’s  legally authorized 
representative  and answer all  questions regarding the study.  
 Participants m ust be informed that their participation is voluntary. Participants or their 
legally authorized representative s will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
privacy an d data protection requirements, where applicable, and the I RB/IEC or study 
center.  
 The medical record must include a statement that written informed consent was obtained 
before the participant was enter ed in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
 Participants must be reconsented to the most current version of the ICF(s) during th eir 
participation in the study.  
 A copy of the ICF(s) must be provided to the participa nt or the participant’s legally 
authorized representati ve and is kept on file . 
10.1.4.  Data Protection   
 Participants will be assigned a unique identifier by the sponsor. Any participant r ecords , 
datasets  or tissue samples  that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant identi fiable 
will not be transferred.  
 The participant must be informed that the participant’s  personal study -related data will be 
used by the sponsor in accordance with local data protection law. The level of disclosure 
must also b e explained to the participant  who will be required to give consent for their 
data to be used as describe d in the informed consent .  
 The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
 The sponsor has processes in place to ensure data  protection, information security , and 
data integrity. These processes include appropriate contingency plan(s) for appropriate 
and timely response in the event of a data security breach.  
10.1.5.  Committees Structure   
Not applicable.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
53 10.1.6.  Dissemination of Clinical Study Data   
Communication of Suspended or Terminated Dosing  
If a decision is taken to suspend or terminate dosing in the trial due to safety findings, this 
decision will be communicated by Lilly to all investigators (for example, by phone and/or email) 
as soon as possible.  It will be a requirement that investigators respond upon receipt to confirm 
that they und erstand the communication and have taken the appropriate action prior to further 
dosing any participants with study intervention.  Any investigator not respond ing will be 
followed up by Lilly personnel  prior to any further planned dosing. If a dose is plann ed 
imminently, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact is made and instructions verified.  
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by local law or regulation.  
The summary of results will be posted within the time frame specified by local law or regulation. 
If the study remains ongoing in some countries and a statistical analysis of an incompl ete data set 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not yet unblinded), the summary of results 
will be submitted within 1 year after the end of t he study globally or as soon as available, 
whichever is earlier.  
Data  
The sponsor does not proactively share data from Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case -by-case basis taking into considerati on the 
ability to anonymize the data and the nature of the data collected.  
10.1.7.  Data Quality Assurance   
 All participant data relating to the study will be recorded on printed or electr onic CRF s 
unless transmitted to the sponsor or designee electronically ( for example , laboratory 
data). The investigator is responsible for verifying that data entries are accurate and 
correct by physically or electronically signing the CRF.  
 The investigato r must maintain accurate documentation (source data) that supports the 
information entered in  the CRF.  
 Source data may include laboratory tests, medical records, and clinical notes.  
 The investigator must permit study -related monitoring, audits, IRB/IEC rev iew, and 
regulatory agency inspections and provide direct a ccess to source data documents.  
 Monitoring details describing strategy ( for example , risk -based initiatives in operations 
and quality such as risk management and mitigation strategies and analytica l risk -based 
monitori ng), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques are provided in the Monitoring Plan . 
 The sponsor or designee is responsible for the data management of this study inc ludin g 
quality checking of the data.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
54  The sponsor assumes accountability for actions delegated to other individuals ( for 
example , contract research organizations ). 
 Study monitors will perform ongoing source data verification to confirm that data 
transcribed  into the CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protoco l and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
 Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the investigator for the time period outlined in the Clinical T rial 
Agreement (CTA)  unless local regulations or institutional policies require a longer 
retention period. No records may be destroyed during the retention period without the 
written approval of the sponsor. No records may be transferred to another locatio n or 
party without written notification to the sponsor . 
 In addition, Sponsor  or its representatives will periodically check a sample of the 
participant  data recorded against source documents at the study site. The study may be 
audited by Sponsor  or its representatives, and/or regulatory agencies at any time. 
Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by the investigator or 
designee into the sponsor -provided EDC sys tem. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by signing the CRF . 
Data collected via the sponsor -provided data capture syste ms will be  stored at third -party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system . Prior to decommissioning, the investigator will receive or access an 
archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferre d from the central vendor to the Sponsor  data 
warehouse.  
Data from complaint forms submitted to the Sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.8.  Source Documents   
 Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the investigator’s site.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
55  Data reported  on or entered in the CRF and are tran scribed from source documents must 
be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending 
on the study. Also, current medical records must  be available.  
 Definition of what constitutes source data can be found in Section  10.1.7 . 
10.1.9.  Study and Site Start and Closure   
First Act of Rec ruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
Study or Site Termination  
The sponsor or spon sor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documen ts and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended terminat ion. 
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:  
For study termination:  
 Discontinuation of further study intervention development  
For site termination:  
 Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
 Inadequate recruitment (evaluated after a reasonable amount of time)  of 
participants by the investigator  
 Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of  the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy   
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer -reviewed journal if the results are deemed to be of significant medica l 
importance.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
56 10.1.11.  Investigator Information   
Not applicable.  
10.1.12.  Long -Term Sample Retention   
Sample retention e nables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of donanemab  or after  donanemab  become(s) commercially available .   
Sample Type  Custodian  Retention Period After Last 
Patient Visit*  
Long -term storage samples  Sponsor or Designee  15 years  
Pharmacokinetic  Sponsor or Designee  2 years  
Genetics  Sponsor or Designee  15 years  
Immunogenicity  Sponsor or Designee  15 years  
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
57 10.2. Appendix 2: Clinical Laboratory Tests   
 The tests detailed in the table below will be performed  by the local laboratory . 
 In circumstances where the sponsor approves local laboratory testing in lieu of central 
laboratory testing (in the table below), the local laboratory must be qualified in 
accordance with applicable local regulations.  
 Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol . 
 Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  
 Investigators must document their review of the laboratory safety results .  
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
58 Safety  Laboratory Tests  
Hematology  Clinical Chemistry  
Hematocrit  Sodium  
Hemoglobin  Potassium  
Erythrocyte count (RBC)  Bicarbonate  
Mean cell volume  Chloride  
Mean cell hemoglobin  Glucose (random ) 
Mean cell hemoglobin concentration  Blood urea nitrogen (BUN) or urea c 
Leukocytes (WBC)  
Platelets  Creatinine  
Uric acid  
 Total cholesterol  
Differential WBC [Absolute counts] of:  Total protein  
Neutrophils  Albumin   
Lymphocytes  Total bilirubin  
Monocytes  Alkaline phosphatase (ALP)  
Eosinophils  Aspartate aminotransferase (AST)  
Basophils  Alanine aminotransferase (ALT)  
 Creatine kinase (CK)  
Urinalysis a Gamma -glutamyl transferase (GGT)  
Specific gravity   
pH  
Protein   
Glucose   
Ketones  Ethanol testing d 
Bilirubin  Urine drug screen d 
Urobilinogen  Hepatitis B surface antigen b 
Blood  Hepatitis C antibody b,e 
Nitrite  HIV e 
Microscopic examination of sediment b Pregnancy testf 
 FSH (postmenopausal females only) b  
Abbreviations: FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; RBC = red blood cells; 
WBC = white blood cells.  
Note: Results of these assays will be validated by the local laboratory at the time of testing.  
a Performed by dipstick.  Microscopic examination to be performed if dipstick is abnormal for blood, protein , or 
nitrates.  
b Performed at screening only . 
c Either BUN or urea will be tested, whichever is feasible.  
d Urine drug screen and ethanol (urine or breath) level performed at screening and at admission to the clinical 
research unit.  
e Participants with a positive hepatitis C antibody test result can have a confirmatory hepatitis C RNA test.  
f In females only. Serum pregnancy test at screening and urine pregnancy test will be  performed at other 
timepoints as indicated in SoA or at investigator’s discretion.  
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
59 10.2.1.  Blood Sampling Summary   
This table summarizes the approximate number of venipunctures and bloo d volumes for all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the study.  
Protocol I5T-MC-AACP Sampling Summary  
 
Purpose  Blood Volume per 
Sample (mL)  Number of Blood 
Samples  Total Volume 
(mL)  
Screening tests a 45 1 45 
Clinical laboratory tests a 12.5 13 162.5  
Pharmacokinetics  4 50 200 
Immunogenicity  10 6 60 
Pharmacogenetics  10 1 10 
Total    477.5  
Total for clinical purposes [rounded up to nearest 10 mL ] 480 
a Additional samples may be drawn if needed for safety purposes.  
 
10.2.2.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event   
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hypersensitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain follow -up predose sampl es at the next regularly scheduled laboratory sample collection 
(ideally prior to the next dose after the event) to assess post -event return -to-baseline values.  
 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
60 Timing  Laboratory Test a 
Collect from 30 minutes to 4 hours after the start of 
the event.  
● Note: The optimal collection time is from 1 to 
2 hours after the start of event.  Total tryptase  
complements ( C3, C3a, and C5a)   
cytokine panel ( IL-6, IL‐1β, IL‐10 or any cytokine 
panel that includes these 3 cytokines)  
Collect only if not already collected on the same day as 
the event.  
● Note: If collecting, collect up to 12 hours after 
the start of the event.  donanemab (LY3002813) ADA  
donanemab (LY3002813)  concentration  
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.  
a All samples for hypersensitivity testing will be assayed by Lilly -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation.  
What information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management . 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
61 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
10.3.1.  Definition of AE   
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease  (new or exacerbated)  
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product . 
 
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for ex ample , ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pr e-existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptom s, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical 
sequelae . 
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
 The disease/dis order being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure ( for example , endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
62  Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing  hospitalization  
 In general, hospitalization signifies that the participant has been admitted to  hospital or 
emergency ward (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physicia n’s office or outpatient 
setting. Complications that occur during hospitalization are AEs. If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious. When 
in doubt as to whether hospitalization occurred or was necessary, the AE should be 
considered serious.  
 Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accide ntal trauma ( for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, feta l death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as important medical 
events that may not be immediately life -threatening or result in death or hospitalization 
but may jeopardize the participant or may require medical or surgical intervention to 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
63 prevent one of the other outcomes listed in the above definiti on. These events should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi talization, or development of drug dependency or 
drug abuse.   
 
10.3.3.  Definition of Product Complaints   
Product Complaint  
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness 
or performance of a study  intervention . When the ability to use the study inter vention 
safely is impacted, the following are also product complaints:  
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
 Product complaints related to study interventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor quality, and to facilitate process and 
product improvements.  
 Investigators will instruct p articipants to contact the site as soon as possible if he o r she 
has a product complaint or problem with the study inte rvention  so that the situation can 
be assessed.  
 An event may meet the definition of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
 
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /product complaint  occurs, it is the responsibility of the investigator 
to review all documentation ( for example , hospital progress notes, laboratory reports, 
and diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /product complaint  information 
in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice . AE/SAE information is reported o n the appropriate  CRF  page and 
product complaint  information is reported on the Product Complaint Form . 
Note: An event may meet the definition of both a product complaint  and an AE/SAE. 
In such cases, it should be reported as both a product complaint  and as an AE/SAE.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
64  It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to Sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the Product Complaint Form for product complaints . 
 There may be instances when copies of m edical records for certain cases are requested 
by Sponsor or designee . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records before 
submission to Sponsor or designee . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .  
Assessment of Intensit y 
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:   
 Mild:  A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
 Moderate:  A type of adverse event that is usually alleviate d with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of adverse event that interru pts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention . 
An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of  an event; and both AEs and SAEs can be 
assessed as severe.  
An event is defined as ‘serious’ when it meets at least one of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship / 
 A “reasonable possibility ” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as  well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB, in their assessment.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
65  For each AE/SAE, the investigator must  document in the medical notes t hat he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor or designee . However, it 
is very i mportant that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to Sponsor or designee . 
 The investigator may change their opinion of causality in light of follow -up 
information and send a SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor or 
designee  to elucidate the nature and/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
66 10.3.5.  Reporting of SAEs   
SAE Rep orting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) in order to report the event within 24 hours.  
 The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
 After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new SAE from a study participant or receives updated 
data on a previou sly reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a SAE paper form (see next 
section) or to the medical monitor/SAE coordinator by telephone.  
 Contacts for SAE reporting can be f ound in the SAE Report . 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the medical monitor or the SAE coordinator . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in the SAE Report.  
10.3.6.  Regulatory Reporting Requireme nts  
SAE Regulatory Reporting  
● Prompt notification by the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study interventio n 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) , and 
investigators.  
● An investigator who receives an investigator safety report describing a SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the sponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropria te according to local requirements.   
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
67 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
 Definition  
Women of childbearing 
potential ( WOCBP)  Adult females are considered WOCBP unless they are WNOCBP . 
Any amount of spotting should be considered menarche.  
Women not of childbearing 
potential  (WNOCBP)  Females are considered WNOCBP  if they  
 have a congenital anomaly such as Müllerian agenesis  
 are infertile due to surgical sterilization, or  
 are postmenopausal.  
Examples of surgical sterilization include total hysterectomy, bilateral 
salpingo -oophorectomy, bilateral salpingectomy, or bilateral oophorectomy.  
Postmenopausal state  The postmenopausal state is defined as a woman:  
 at any age at least 6 weeks postsurgical bilateral oophorectomy with 
or without hysterectomy, confirmed by operative note; or  
 aged at least 40 years and up to 55 years wit h an intact uterus, not on 
hormone therapy a, who has had cessation of menses for at least 
12 consecutive months without an alternative medical cause, AND 
with a follicle -stimulating hormone >40 mIU/mL; or  
 55 years or older not on hormone therapy, who has had at least 
12 months of spontaneous amenorrhea, or  
 aged at least 55 years with a diagnosis of menopause prior to starting 
hormone replacement therapy.  
a Women should not be taking medications during amenorrhea such as oral contraceptives, hormones, 
gona dotropin -releasing hormone, anti -estrogens,  selective estrogen receptor modulators , or chemotherapy that 
could induce transient amenorrhea.  
 
Females  
Topic  Condition  
Pregnancy testing  Have a negative serum test result at screening followed by a negative urine result 
within 24 hours prior to treatment exposure. See the protocol Schedule of Activities 
for subsequent pregnancy testing requirements.  
Contraception  Abstinence or 2 effective forms of contraception where at least 1 form is highly 
effective, main tained for at least 5 half -lives plus 30 days  
 
10.4.2.  Contraception Guidance   
For male participants:  
 Males may participate in this study . 
 No male contraception is required except in compliance with specific local government 
study requirements.  
For female participants:  
 Women of childbearing potential  are excluded from the study . 
 Women not of childbearing potential  may participate in this study . 
See Appendix 4, Section 10.4.1  for definitions.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
68 Examples of highly effective, effective, and unacceptable methods of contraception  can be found 
below.  
Methods  Examples  
Highly effective 
contraception (less than 1% 
failure rate)   female sterilization  
 combination oral contraceptive pill  
 progestin -only contraceptive pill (mini -pill) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopian tube implants (if confirmed by hysterosalpingogram)  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide  
Ineffective forms of 
contraception whether used 
alone or in any 
combination   spermicide alone  
 periodic  abstinence  
 fertility awareness (calendar method, temperature method, cervical 
mucus, or symptothermal)  
 withdrawal  
 postcoital douche, or  
 lactational amenorrhea  
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
69 10.5. Appendix  5: Genetics   
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolism, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a blood sample will be 
collected for DNA analysis from consenting participants.  
● DNA samples will be used for research related to donanemab  and related 
diseases. They may also be used to develop tests/assays including diagno stic tests 
related to  donanemab  and/or interventions of this drug class . Genetic research 
may consist of the analysis of one or more candidate genes or the analysis of 
genetic markers throughout the genome or analysis of the entire genome  (as 
appropriate).  
● DNA samples will be analyzed for apolipoprotein E genotype ε4. Additional 
analyses may be conducted if it is hypothesized that this may help further 
understand the clinical data.  
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in the response to donanemab  or study interventions of this class 
to understand study disease or related conditions.  
● The results of genetic analyses may be reported i n the clinical study report or in a 
separate study summary.  
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on donanemab  or study interventi ons 
of this class or indication  continues but no longer than 15 years or other period as 
per local requirements.  
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
70 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
Hepatic Evaluation Testing  
See Section 8.2.8.1  for guidance on appropriate test selection.  
Testing by an investigator -designated local laboratory should be performed for all testing defined 
by this guidance.  
The local laboratory must be q ualified in accordance with applicable local regulations.  
Hepatic Hematology Panel  Hepatic Clinical Chemistry Panel   
   Hemoglobin     Total bilirubin  
   Hematocrit     Direct bilirubin  
   Erythrocytes (RBCs - red blood cells)     Alkaline phosphatase (ALP)  
   Leukocytes (WBCs - white blood cells)     Alanine aminotransferase (ALT)  
   Differential:     Aspartate aminotransferase (AST)  
       Neutrophils, segmented     Gamma -glutamyl transferase (GGT)  
       Lymphocytes     Creati ne kinase (CK)  
       Monocytes  Other Chemistry  
       Basophils     Acetaminophen  
       Eosinophils     Acetaminophen protein adducts  
   Platelets     Alkaline phosphatase isoenzymes  
   Cell morphology (RBC and WBC)     Ceruloplasmin  
Hepatic Coagulation Panel     Copper  
    Prothrombin time, INR (PT -INR)     Ethyl alcohol (EtOH)  
Hepatitis A virus (HAV) testing:     Haptoglobin  
    HAV total antibody     Immunoglobulin IgA (quantitative)  
    HAV IgM antibody     Immunoglobulin IgG (quantitative)  
Hepatitis B virus (HBV) testing:     Immunoglobulin IgM (quantitative)  
    Hepatitis B surface antigen (H bsAg)     Phosphatidylethanol (P eth) 
    Hepatitis B surface antibody (anti -HBs)  Urine Chemistry  
    Hepatitis B core total antibody (anti -HBc)     Drug screen  
    Hepatitis B core IgM antibody     Ethyl glucuronide (EtG)  
    HBV DNA  b Other Serology  
Hepatitis C virus (HCV) testing:     Anti-nuclear antibody (ANA)  
    HCV antibody     Anti-smooth muscle antibody (ASMA) a 
    HCV RNA  b    Anti-actin antibody c 
Hepatitis D virus (HDV) testing:     Epstein -Barr virus (EBV) testing:  
    HDV antibody         EBV antibody  
Hepatitis E virus (HEV) testing:         EBV DNA  b 
    HEV IgG antibody     Cytomegalovirus (CMV) testing:  
    HEV IgM antibody         CMV antibody  
    HEV RNA b        CMV DNA  b 
Microbiology      Herpes simplex virus (HSV) testing:  
   Culture:         HSV (Type 1 and 2) antibody  
       Blood         HSV (Type 1 and 2) DNA  b 
       Urine     Liver kidney microsomal type 1 (LKM -1) antibody  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
71 Abbreviations: Ig = immunoglobulin; INR = international normalized ratio ; PT-INR = prothrombin 
time-international normalized ratio . 
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
72 10.7. Appendix 7: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator.  
Exceptional circumstances  
Exceptional circumstances are rare events that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulations.  
After approval by local Ethical Review Boards, regulatory bodies and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typically require 
additio nal notification to these groups, unless they have specific requirements in which 
notification is required (for example, upon implementation and suspension of changes). All 
approvals and notifications must be retained in the study records.  
If the sponsor g rants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with Good Clinical 
Practice, enabling participants to continue safely in the study and mai ntaining the integrity of the 
study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for:  
 participation in remote visits, as defined in Section “Remote Visits ,” and 
 provision of their personal or medical information  required prior to implementation of 
these activities.  
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following c hanges in study conduct will not be considered protocol deviations.  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
73 Remote visits  
Types of remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments. Assessments to be completed in this manner include, 
but are not limited to, AEs and  concomitant medications .  
Other alternative locations : Partici pants may visit local hospital other than the study 
site when participants cannot travel to the site due to an exceptional circumstance if 
written approval is provided by the sponsor. Procedures performed at such visits include 
but are not limited to safet y monitoring (physical examination, vital signs, ECG, body 
temperature, neurological examinations), sample collections for clinical laboratory tests.  
 
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of adverse events (AEs), serious adverse events (SAEs), and product complaints 
remain unchanged.  
Return to on -site visits  
Every effort should be made to  enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff.  
Screening period guidance   
To ensure safety of study participants, laboratory values and other eligibili ty assessments taken 
at screening visit  are valid for a maximum of 28 days. The following rules will be applied for 
active, nonrandomized participants whose participation in the study must be paused due to 
exceptional circumstances:  
 If screening is paused for less than 28 days from screening visit to randomization 
visit: the participant will proceed to the next study visit per the usual Schedule of 
Activities, provided that randomization visit  must be conducted within 28 days from 
first screening visit.  
o The site should conduct the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document th is confirmation in the source 
documentation.  
 If screening is paused for more than 28 days from screening visit to randomization 
visit: The participant must be discontinued because of screening interruption due to 
an exceptional circumstance.  The participan t can reconsent and be rescreened as a 
new participant. The screening procedures per the usual Schedule of Activities should 
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
74 be followed, starting at screening visit to ensure participant eligibility by 
randomization visit.  
Adjustments to visit windows  
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual Schedule of Activities. To maximize the possibility that these visits 
can be conducted as on -site visits, the windows for visits may b e adjusted, upon further guidance 
from the sponsor. This minimizes missing data and preserves the intended conduct of the study.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and document the details of how participants, visits types, and conducted 
activities were affected by exceptional circumstances. Dispensing/shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents at alternate l ocations  
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
 
 
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
75 10.8. Appendix 8: Abbreviations  and Definitions   
Term  Definition  
Aβ amyloid beta  
abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
AD Alzheimer’s disease  
ADA  anti-drug antibody  
AE adverse event  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ApoE4  apolipoprotein E genotype ε4  
ARIA  amyloid -related imaging abnormalities  
ARIA -E ARIA –edema/effusions  
ARIA -H ARIA –hemorrhage/hemosiderin deposition  
AST aspartate aminotransferase  
AUC 0-4Weeks  area under the concentration versus time curve 0 to 4 weeks  
AUC 0-∞ area under the concentration versus time curve from time 0 to infinity  
AUC 0-tlast area under the concentration versus time curve from time 0 to last measured 
concentratio n 
AUC,ss area under the concentration versus time curve during a dosing interval at steady state  
BMI body mass index  
CDC  Centers for Disease Control and Prevention  
Cmax maximum observed drug concentration  
Cmax,ss  maximum observed  drug concentration during a dosing interval at steady state  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
Compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
COVID -19 coronavirus disease 2019  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
76 CRF case report form; a  printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial participant . 
CRP  clinical research physician:  Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician or other medical officer.  
CRU  clinical research unit  
C-SSRS  Columbia -Suicide Severity Rating Scale  
ECG  electrocardiogram  
enroll  The act of assigning a participant  to a treatment. Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
Enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their l egally acceptable representatives.  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
iADRS  integrated Alzheimer’s Disease Rating Scale  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IMP Investigational Medicinal Product (see also “ investigational product ”) 
A medicinal product which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
informed consent  A process by which a participant  voluntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s  decision to participate. Informed co nsent is documented by 
means of a written, signed and dated informed consent form . 
INR international normalized ratio  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about th e authorized form.  See also “IMP.”  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
77 IRB Institutional Review Board  
IRR infusion -related reactions  
IV intravenous  
MCI mild cognitive impairment  
N3pG  pyroglutamate formation of the third amino acid  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control  
PC product complaint  
PCR  polymerase chain reaction  
PK pharmacokinetics  
PT-INR prothrombin time -international normalized ratio  
Q2W  every 2 weeks  
Q4W  every 4 weeks  
QTc corrected QT interval  
SAE serious adverse event  
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus  
screen  The act of determining if an individual meets minimum requirements t o become part of 
a pool of potential candidates for participation in a clinical study.  
SIB suicidal ideation and behavior  
SoA Schedule of Activities  
TBL total bilirubin level  
TE-ADA  treatment -emergent anti -drug antibodies  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
ULN upper limit of normal  
  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
78 11. References   
Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid -β 
on clinical and biomarker outcomes and adverse  event risks: a systematic review and 
meta -analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev . 2021;68:101339. 
https://doi.org/ 10.1016/j.arr.2021.101339  
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on 
the road to therapeutics. Science . 2002;297(5580):353 -356. 
https://doi.org/ 10.1126/science.1072994  
Hyman BT, Phelps CH, Beach TG,  et al. National Institute on Aging –Alzheimer ’s Association 
guidelines on neuropathologic assessment of Alzheimer ’s disease. Alzheimers Dement . 
2012;8(1):1 -13. https://doi.org/ 10.1016/j.jalz.2011.10.007  
Jack CR Jr, Knopman DS, Jagust WJ,  et al. Hypothetical model of dynamic biomarkers of th e 
Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119 -128. 
https://doi.org/ 10.1016/S1474 -4422(09)70299 -6 
Ketter N, Brashear HR, Bogert J, et al. Central review of amyloid -related imaging abnormalities 
in two phase III clinical trials of bapineuz umab in mild -to-moderate Alzheimer’s disease 
patients. J Alzheimers Dis. 2017;57(2):557 -573. https://doi.org/10.3233/JAD -160216  
Mintun MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer’s disease . N Engl J Med . 
2021;384(18):1691 -1704. https://doi.org/10.1056/NEJMoa2100708  
Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, 
and early -stage Alzheimer’s disease. J Mol Neurosci . 2001;17(2):101 -118. 
https://doi.org/ 10.1385/jmn:17:2:101  
Ostrowitzki S, D eptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with 
Alzheimer disease treated with gantenerumab. Arch Neurol . 2012;69(2):198 -207. 
https://doi.org/10.1001/archneurol.2011.1538  
Sampson HA, Muñoz -Furlong A, Campbell RL,  et al. Second s ymposium on the definition and 
management of anaphylaxis: summary report --Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin 
Immunol . 2006 ;117(2):391 -7. https:// doi.org/10.1016/j.jaci. 2005.12.1303  
Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron . 1991;6(4):487 -498. 
https://doi.org/ 10.1016/0896 -6273(91)90052 -2 
Sperling R, Salloway S, Brooks DJ, et al. Amyloid -related imaging abnormalities in patients 
with Alzheimer’s dis ease treated with bapineuzumab: a retrospective analysis. Lancet Neurol . 
2012;11(3):241 -249. https://doi.org/10.1016/S1474 -4422(12)70015 -7 
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double -blind, phase 2b proof -of-concept 
clinical trial in early A lzheimer's disease with lecanemab, an anti -Aβ protofibril antibody. 
Alzheimers Res Ther . 2021;13(1):80. https://doi.org/10.1186/s13195 -021-00813 -8 
VandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amyloid -related imaging 
abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst) . 
2020;12(1):e12101. https://doi.org/10.1002/dad2.12101  
Approved on 12 Dec 2022 GMT
CONFIDENTIAL  I5T-MC-AACP (a) 
79 Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for 
clinical trials: the integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alz heimers  
Dis. 2015;2(4):227 -241. https://doi.org/ 10.14283/jpad.2015.82  
Approved on 12 Dec 2022 GMT
Signature Page for VV-CLIN-076261 v1.0
Signature Page for VV-CLIN-076261 v1.0Approval
Statistician
12-Dec-2022 14:01:04 GMT+0000
Approval
Medical Director
12-Dec-2022 17:51:43 GMT+0000
Approved on 12 Dec 2022 GMT
PPD
PPD